%0 Figure %A Asselah, Tarik %A Moreno, Christophe %A Sarrazin, Christoph %A Gschwantler, Michael %A R. Foster, Graham %A CraxĂ­, Antonio %A Buggisch, Peter %A Sanai, Faisal %A Bicer, Ceyhun %A Lenz, Oliver %A Van Dooren, Gino %A Nalpas, Catherine %A Lonjon-Domanec, Isabelle %A Schlag, Michael %A Buti, Maria %D 2017 %T Eligibility for 12-week simeprevir plus PR regimen according to patient baseline characteristics. %U https://plos.figshare.com/articles/figure/Eligibility_for_12-week_simeprevir_plus_PR_regimen_according_to_patient_baseline_characteristics_/4521269 %R 10.1371/journal.pone.0168713.g002 %2 https://ndownloader.figshare.com/files/7322135 %K on-treatment virologic response %K 12 weeks %K virologic response 12 weeks post-treatment %K HCV GT 4 infection %K 12- week group %K SVR 12. Methods %K 48- week combination regimen %K 24- week group %K safety signals %K simeprevir %K METAVIR %K On-Treatment Virologic Response Background HCV GT 4 accounts %K Primary study objectives %K Hepatitis C Virus %K Primary efficacy outcome %K favourable baseline characteristics %K 67 patients %K virologic response %K 12- week treatment %K CT %K RNA %K Week 24. Results %K IL 28B CC patients %K IU %K HCV GT 4 %K NCT %K PR therapy %X

Eligibility for 12-week simeprevir plus PR regimen according to patient baseline characteristics.

%I PLOS ONE